"The voice for cancer physicians and their patients in Massachusetts."

Drug Updates

The latest drug updates, protocol listings & industry news.

  • Updates Healthcare Common Procedure Coding System Code (HCPCS) and dose descriptor for Amgen's Neulasta® (pegfilgrastim) Onpro® and Neulasta®
    08 DEC 2021

    Neulasta® (pegfilgrastim) Onpro® and Neulasta® have an updated Healthcare Common Procedure Coding System (HCPCS) Code and dose descriptor, effective January 1, 2022.

    The UPDATED HCPCS CODE is J2506

    The UPDATED DOSE DESCRIPTOR is Injection, pegfilgrastim, excludes biosimilar, 0.5 mg

    This updated dose descriptor can be billed in multiple units to accommodate a variety of doses. Providers should note the new dose descriptor is now 0.5 mg. Per label, the dose for Neulasta® (pegfilgrastim) is 6 mg. Please accurately report service units when billing.

    Key dates:

    • For dates of service on and after January 1, 2022, providers must use the updated HCPCS Code J2506, and dose descriptor, and discontinue use of the HCPCS Code J2505, as it will no longer be accepted
    • Providers may only use J2505 for dates of service on or before December 31, 2021

    Information on the updated code and dose descriptor is summarized in the following attachments:

    Neulasta® (pegfilgrastim) Onpro® and Neulasta® J-Code Flashcard, which contains the effective date, coding, and support service information and Neulasta® (pegfilgrastim) Onpro® and Neulasta® Billing and Coding Guide, which will provide you with detailed coding, dosing and administration, and support service information.

    Hospital Outpatient Coding and Billing Information Sheet

    Physician Office Coding and Billing Information Sheet

    Please see full Prescribing Information for Neulasta® (pegfilgrastim) Onpro® and Neulasta® by clicking the link below:

    Neulasta® Prescribing Information

  • Updates for Bristol Myers Squibb's ISTODAX® for injection, for intravenous use
    20 Oct 2021

    The CMS 2021 ASP Drug Pricing Files for the 4th quarter effective October 1, 2021 through December 31, 2021 reflects updates for ISTODAX® (romidepsin) for injection, for intravenous use.  The update includes the following changes which are effective October 1, 2021:

    • Discontinued HCPCS Code J9315 “Injection, romidepsin, 1mg” on September 30, 2021 and established J9319 “Injection, romidepsin, lyophilized, 0.1mg” on October 1, 2021.
    • Changed the HCPCS Code Dosage from 1mg to 0.1 mg.

    Per CMS, this change in J-code needed to be made because: “A new HCPCS code for Romidepsin Injection, non-lyophilized liquid is needed because it is a single source drug approved under a unique NDC number, and it needs to be differentiated from the existing HCPCS code for a multi-sourced Romidepsin drug in lyophilized powder form.”

  • Understanding the Biden Administration's Drug Pricing Plan
    20 Oct 2021
    The Department of Health and Human Services released the administration’s Comprehensive Plan for Addressing High Drug Prices in response to President Biden’s executive order that identified a lack of industry competition as a key driver of high drug prices. Read More.
  • New permanent J-Code for COSELA (trilaciclib)
    01 Oct 2021

    G1 Therapeutics, Inc. secures permanent J Code for COSELA™ (trilaciclib). The code, J1448, is effective on October 1, 2021. Visit COSELA.com for more information.

  • New permanent J-Code for Melphalan Flufenamide
    01 Oct 2021

    Oncopeptides announces J-code J9247 for Pepaxto® (melphalan flufenamide) injection, 1mg. This J-code will be effective on October 1, 2021.

  • Novartis presents new Kisqali® (ribociclib) data showing longest median overall survivial ever reporterd in HR+/HER2- advanced breast cancer 
    19 sep 2021
    Novartis announced results of the final overall survival (OS) analysis of the Phase III MONALEESA-2 study, which evaluated Kisqali® (ribociclib) in combination with letrozole compared to placebo plus letrozole in postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced or metastatic breast cancer with no prior systemic treatment for advanced disease. These data will be presented as a late-breaker oral presentation at the European Society for Medical Oncology (ESMO) Congress 2021 on September 19 (#LBA17).  Read More
  • The Centers for Medicare and Medicaid Services (CMS) has issued a J-Code for ENHERTU (fam-trastuzumab deruxtecan-nxki)
    01 Jul 2020

    Effective July 1, 2020, the following code J9358 can be used to identify ENHERTU® (fam-trastuzumab deruxtecan-nxki) when billing across settings of care as noted in the CMS HCPCS Application Summaries and Coding Decisions.


  • The Centers for Medicare and Medicaid Services (CMS) has issued a J-Code for PADCEV (enfortumab-vendotin ejfv)
    01 Jul 2020

    Astellas announces the assignment of a product-specific, permanent J-code for PADCEV. The Centers for Medicare & Medicaid Services (CMS) released the July 2020 Quarterly Healthcare Common Procedural Coding System (HCPCS) File, which includes the designation of J9177 for PADCEV with the effective date of July 1, 2020. 


© Copyright.  All rights reserved. 

Massachusetts Society of Clinical Oncologists

P.O. Box 549154, Waltham, MA, 02454
Tel: 781.434.7329 | Fax: 781.464.4896 | email: msco@mms.org

Powered by Wild Apricot Membership Software